A newly engineered cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs, triggering whole-body tumor destruction when injected directly into tumors instead of delivered through the bloodstream. In a small clinical trial of 12 patients with metastatic cancers, six saw their tumors shrink and two experienced complete remission, meaning all detectable cancer disappeared. What Makes This CD40 Therapy Different From Previous Attempts? For more than 20 years, scientists explored a group of cancer drugs called CD40 agonist antibodies, which were designed to activate the immune system and help it destroy cancer cells. However, early clinical trials showed only modest benefits, and the drugs often caused serious side effects such as widespread inflammation, dangerously low platelet levels, and liver damage, even at relatively low doses. In 2018, researchers led by Jeffrey V. Ravetch at Rockefeller University redesigned a CD40 agonist antibody to improve its effectiveness while reducing harmful side effects. The team engineered the antibody, called 2141-V11, with two key improvements: - Molecular Design: The redesigned antibody binds tightly to human CD40 receptors and was modified to improve crosslinking by interacting with a specific Fc receptor, making it about 10 times more effective at triggering an immune attack against tumors. - Delivery Method: Instead of traditional intravenous infusion, which exposed healthy cells throughout the body to the drug and caused toxic side effects, researchers injected the treatment directly into tumors. - Safety Profile: When injected directly into tumors, the therapy caused only mild toxicity, avoiding the severe side effects seen in previous CD40 drug trials. CD40 is a receptor found on the surface of immune cells that belongs to the tumor necrosis factor receptor superfamily. When CD40 is activated, it signals the immune system to mount a stronger response, helping trigger anti-tumor immunity and generate cancer-targeting T cells. How Did Tumors Disappear Without Being Injected? One of the most remarkable findings from the trial was that the treatment did not only affect the tumors that were directly injected with the drug. Tumors located elsewhere in the body also shrank or were eliminated by immune cells. "When we did that, we saw only mild toxicity. This effect, where you inject locally but see a systemic response, that's not something seen very often in any clinical treatment. It's another very dramatic and unexpected result from our trial," said Jeffrey V. Ravetch. Jeffrey V. Ravetch, Researcher at Rockefeller University The trial involved 12 people with several types of metastatic cancer, including melanoma, renal cell carcinoma, and different forms of breast cancer. The two patients whose cancer vanished completely had melanoma and breast cancer, respectively, both known for being aggressive and prone to recurrence. In one striking example, a melanoma patient had dozens of metastatic tumors on her leg and foot, but researchers injected just one tumor on her thigh. After multiple injections of that single tumor, all the other tumors disappeared. Similarly, a patient with metastatic breast cancer had tumors in her skin, liver, and lung, but only the skin tumor was injected, yet all tumors vanished. What Happens Inside the Tumor When the Drug Works? Samples taken from treated tumors revealed how powerfully the immune system responded to the therapy. Researchers discovered that the tumors became filled with immune cells, including dendritic cells, T cells, and mature B cells, which formed aggregates resembling lymph nodes. "We were quite surprised to see that the tumors became full of immune cells that formed aggregates resembling something like a lymph node. The drug creates an immune microenvironment within the tumor, and essentially replaces the tumor with these tertiary lymphoid structures," explained Juan Osorio. Juan Osorio, Visiting Assistant Professor at Rockefeller University and Medical Oncologist at Memorial Sloan Kettering Cancer Center These structures, known as tertiary lymphoid structures (TLS), are often linked to better outcomes in cancer treatment and stronger responses to immunotherapy. Researchers also detected TLS in tumors that were not directly injected with the drug, suggesting that once the immune system identifies the cancer cells, immune cells migrate to non-injected tumor sites. What's Next for This Immunotherapy Approach? The promising findings have led to additional clinical trials. Ravetch's group is now collaborating with scientists at Memorial Sloan Kettering and Duke University to further evaluate the therapy. Current phase 1 and phase 2 trials are testing 2141-V11 against several difficult-to-treat cancers, including bladder cancer, prostate cancer, and glioblastoma, with nearly 200 patients participating across these studies. Researchers hope the larger trials will reveal why some patients respond to the treatment while others do not, and how response rates might be improved. The two patients whose cancer disappeared completely both showed high clonality of T cells when the trial began, meaning they had a robust population of immune cells already primed to fight cancer. "This suggests there are some requirements from the immune system in order for this drug to work, and we're in the process of dissecting these characteristics in more granular detail in these larger studies," noted Juan Osorio. Juan Osorio, Visiting Assistant Professor at Rockefeller University and Medical Oncologist at Memorial Sloan Kettering Cancer Center Understanding these factors could help researchers predict who will benefit from the therapy. As a general rule, only 25 to 30 percent of patients respond to immunotherapy, so the biggest challenge in the field is determining which patients will benefit from it and how to convert non-responders into responders. How to Stay Informed About Cancer Immunotherapy Advances - Clinical Trial Databases: Check ClinicalTrials.gov regularly to learn about new immunotherapy trials in your area, including those testing CD40 agonist antibodies and other checkpoint inhibitors for your specific cancer type. - Oncologist Consultations: Discuss with your cancer care team whether you might be eligible for emerging immunotherapy trials, especially if standard treatments have not been effective or if you have aggressive cancers like melanoma or metastatic breast cancer. - Research Institution Updates: Follow major cancer research centers like Rockefeller University, Memorial Sloan Kettering, and Duke University for announcements about new trial phases and expanded patient enrollment opportunities. The redesigned CD40 therapy represents a significant shift in how researchers approach cancer immunotherapy. By combining a more powerful antibody design with a smarter delivery method, scientists have overcome decades of setbacks and opened a new pathway for treating aggressive, metastatic cancers. While the trial was small, the results suggest that this approach could eventually help many more patients achieve remission and improve survival rates across multiple cancer types.
